New drug shrinks cancer, with few side effectsApril 7th, 2011 - 2:41 pm ICT by ANI
Washington, April 7 (ANI): Scientists at the University of Michigan Comprehensive Cancer Center showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.
The study, done in two mouse models of human cancer, looked at two compounds designed to activate a protein that kills cancer cells.
The protein, p53, is inactivated in a significant number of human cancers. In some cases, it is because another protein, MDM2, binds to p53 and blocks its tumor suppressor function.
This allows the tumor to grow unchecked. The new compounds block MDM2 from binding to p53, consequently activating p53.
“For the first time, we showed that activation of p53 by our highly potent and optimized MDM2 inhibitors can achieve complete tumor regression in a mouse model of human cancer,” said lead study author Shaomeng Wang.
Many traditional cancer drugs also activate p53 but they do so by causing DNA damage in both tumor cells and normal cells, causing side effects.
These new MDM2 inhibitors activate p53 while avoiding the DNA damage common with other drugs. In this study researchers showed that these new drugs shrank tumors without significant side effects.
Because p53 is involved in all types of human cancer, the new drug has potential to be used in multiple types of cancer.
Further, the researchers also identified certain markers in tumors that predict which ones will be particularly sensitive to the MDM2 inhibitor, which would allow physicians to target the drug only to patients most likely to benefit.
The study was presented at the American Association for Cancer Research 102nd annual meeting. (ANI)
- Small molecule may deactivate enemy of cancer-fighting p53 - Dec 08, 2010
- Overabundance of protein promotes growth of breast cancer stem cells - Feb 16, 2011
- Genetic change helps lung tumors spread to other parts of the body - Apr 07, 2011
- Small molecules 'could block cell proliferation in cancerous human tumor' - Apr 14, 2011
- 'Smart' lung cancer drug shows promise - Oct 28, 2010
- Compound used to control cholesterol may also kill breast cancer - Feb 23, 2011
- New 'nanodrug' can attack breast cancer cells from the inside out - Mar 30, 2011
- Arsenic could be a potential cancer treatment - Jul 13, 2010
- Soy 'ups radiation's ability to destroy lung cancer cells' - Apr 02, 2011
- Blocking DNA repair protein likely to make cancer therapy safer - Jun 02, 2010
- New fusion molecule 'empowers immune system to fight cancer' - Apr 13, 2011
- Novel immune therapy for pancreatic cancer discovered - Mar 25, 2011
- Boffins design new class of drug that kills lymphoma cells - Apr 15, 2010
- Synthetic compound may lead to drugs to fight pancreatic, lung cancer - Mar 10, 2011
- New therapeutic target for lung cancer identified - Apr 01, 2011
Tags: cancer cells, cancer drug, cancer drugs, cancer research, comprehensive cancer center, dna damage, drug compounds, human cancer, human cancers, mdm2, michigan comprehensive cancer, mouse model, mouse models, new drugs, protein p53, study researchers, tumor cells, tumor regression, types of cancer, university of michigan comprehensive cancer center